Deardorf Caren 4

What Happened
Caren Deardorf, a member of Crinetics Pharmaceuticals' (CRNX) board of directors, received equity awards on 2026-06-18: 5,925 restricted stock units (RSUs) and a separate 9,730-share derivative award (option-type grant). Both awards were reported at $0.00 (no cash paid) in the Form 4 filed 2026-06-22.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (4 days after the transaction).
• Awards: 5,925 RSUs (reported as acquired, $0.00) and 9,730-share derivative award/option (reported as acquired, $0.00).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes:
  • RSUs (5,925): 100% vest on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting, subject to continued board service.
  • Derivative/option (9,730): vests and becomes exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting, subject to continued board service.
• Timing note: Form 4 was filed 4 days after the award date; Form 4s are generally required within two business days of the transaction, so the filing timing may be later than typical.

Context

• These are grants/awards (compensation) to a director, not open-market purchases or sales; such awards are routine for director compensation and do not by themselves indicate intent to buy or sell stock.
• The derivative award is an option-like grant that must vest/exercise per the footnote schedule before converting to shares; RSUs convert to shares upon vesting.